Anticoagulation Therapy for Atrial Fibrillation After Transcatheter Aortic Valve Replacement: National Database Insights
DOAC use in patients with AF who undergo TAVR may be preferable to VKA use in a real-world clinical setting.
Authors
- Tomoya Myojin (ORCID: https://orcid.org/0000-0002-3820-6157)
- Tatsuya Noda (ORCID: https://orcid.org/0000-0002-3652-7547)
- Tomoaki Imamura (ORCID: https://orcid.org/0000-0003-1981-9959)
- Koki Takegawa (ORCID: https://orcid.org/0009-0004-3120-218X)
- Yuichi Nishioka (ORCID: https://orcid.org/0000-0002-1956-3925)
- Yoshitaka Iwanaga (ORCID: https://orcid.org/0000-0002-1391-2864)
- Koshiro Kanaoka (ORCID: https://orcid.org/0000-0001-7900-7835)
- Tetsuo Sasano (ORCID: https://orcid.org/0000-0003-3582-6104)
- Yoshihiro Miyamoto (ORCID: https://orcid.org/0000-0002-1337-0508)
Institutions
- Cardiovascular Institute Hospital (JP)
- Shanghai Institute for Science of Science (CN)
- National Cerebral and Cardiovascular Center (JP)
- Nara Medical University Hospital (JP)
- Sakurabashi Watanabe Hospital (JP)
- Institute of Science Tokyo (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1161/jaha.124.040030
- Citations
- 2
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78